Open Access

The effect of an alternative chromosome 17 probe on fluorescence in situ hybridization for the assessment of HER2 amplification in invasive breast cancer

  • Authors:
    • Zhigao Xu
    • Peipei Xu
    • Wei Fan
    • Ben Huang
    • Qingyuan Cheng
    • Zheng Zhang
    • Ping Wang
    • Mingxia Yu
  • View Affiliations

  • Published online on: July 9, 2019     https://doi.org/10.3892/etm.2019.7756
  • Pages: 2095-2103
  • Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Fluorescent in situ hybridization (FISH) is commonly used to determine the ratio of human epidermal growth factor receptor 2 (HER2) to centromere enumeration probe for chromosome 17 (CEP17), which further determines HER2 gene status in breast cancer. However, due to copy number alteration in CEP17, inaccurate diagnoses can occur. The current study was performed to investigate the diagnostic value of an alternative CEP17 reference probe for HER2 status in invasive breast cancer. A higher‑order repeat in the centromeric region of chromosome 17 was identified and an alternative probe (SCEP17) was subsequently prepared. Karyotype analysis of peripheral blood was used to detect SCEP17 probe specificity. Using a HER2/CEP17 probe, karyotype analysis revealed two strong green signals at the centromere of chromosome 17 and one weaker signal at the other centromere. However, two strong hybridization signals at the centromere of chromosome 17 were observed when the HER2/SCEP17 probe was used. In the 425 patients with invasive breast cancer, no statistical difference was observed between HER2/SCEP17 and HER2/CEP17 when detecting HER2 gene amplification (P=0.157). However, in terms of copy number, the SCEP17 probe exhibited a reduced number compared with the conventional CEP17 probe (P<0.001). In conclusion, the HER2/SCEP17 probe may lead to increased accuracy HER2 status assessment in invasive breast cancer. However, a further large‑scale and prospective clinical trial is required for confirmation of the potential benefits of using the HER2/SCEP17 probe.

References

1 

Krishnamurti U and Silverman JF: HER2 in breast cancer: A review and update. Adv Anat Pathol. 21:100–107. 2014. View Article : Google Scholar : PubMed/NCBI

2 

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI

3 

Lal P, Salazar PA, Hudis CA, Ladanyi M and Chen B: HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: A single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol. 121:631–636. 2004. View Article : Google Scholar : PubMed/NCBI

4 

Varga Z, Noske A, Ramach C, Padberg B and Moch H: Assessment of HER2 status in breast cancer: Overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: A quality control study. BMC Cancer. 13:6152013. View Article : Google Scholar : PubMed/NCBI

5 

Esteva FJ and Hortobagyi GN: Prognostic molecular markers in early breast cancer. Breast Cancer Res. 6:109–118. 2004. View Article : Google Scholar : PubMed/NCBI

6 

Tandon AK, Clark GM, Chamness GC, Ullrich A and McGuire WL: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 7:1120–1128. 1989. View Article : Google Scholar : PubMed/NCBI

7 

Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH and Levine MN; National Cancer Institute of Canada Clinical Trials Group, : HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 354:2103–2111. 2006. View Article : Google Scholar : PubMed/NCBI

8 

Ménard S, Valagussa P, Pilotti S, Gianni L, Biganzoli E, Boracchi P, Tomasic G, Casalini P, Marubini E, Colnaghi MI, et al: Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol. 19:329–335. 2001. View Article : Google Scholar : PubMed/NCBI

9 

De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G, et al: A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res. 11:4741–4748. 2005. View Article : Google Scholar : PubMed/NCBI

10 

Guiu S, Gauthier M, Coudert B, Bonnetain F, Favier L, Ladoire S, Tixier H, Guiu B, Penault-Llorca F, Ettore F, et al: Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer. Br J Cancer. 103:1335–1342. 2010. View Article : Google Scholar : PubMed/NCBI

11 

Saini KS, Azim HA Jr, Metzger-Filho O, Loi S, Sotiriou C, de Azambuja E and Piccart M: Beyond trastuzumab: new treatment options for HER2-positive breast cancer. Breast. 20 (Suppl 3):S20–S27. 2011. View Article : Google Scholar : PubMed/NCBI

12 

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 31:3997–4013. 2013. View Article : Google Scholar : PubMed/NCBI

13 

Rosa FE, Santos RM, Rogatto SR and Domingues MA: Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas. Braz J Med Biol Res. 46:207–216. 2013. View Article : Google Scholar : PubMed/NCBI

14 

Dal Lago L, Durbecq V, Desmedt C, Salgado R, Verjat T, Lespagnard L, Ma Y, Veys I, Di Leo A, Sotiriou C, et al: Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther. 5:2572–2579. 2006. View Article : Google Scholar : PubMed/NCBI

15 

Vanden Bempt I, Van Loo P, Drijkoningen M, Neven P, Smeets A, Christiaens MR, Paridaens R and De Wolf-Peeters C: Polysomy 17 in breast cancer: Clinicopathologic significance and impact on HER-2 testing. J Clin Oncol. 26:4869–4874. 2008. View Article : Google Scholar : PubMed/NCBI

16 

Vanden Bempt I, Drijkoningen M and De Wolf-Peeters C: The complexity of genotypic alterations underlying HER2-positive breast cancer: An explanation for its clinical heterogeneity. Curr Opin Oncol. 19:552–557. 2007. View Article : Google Scholar : PubMed/NCBI

17 

Gunn S, Yeh IT, Lytvak I, Tirtorahardjo B, Dzidic N, Zadeh S, Kim J, McCaskill C, Lim L, Gorre M and Mohammed M: Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity. BMC Cancer. 10:3962010. View Article : Google Scholar : PubMed/NCBI

18 

Forozan F, Mahlamäki EH, Monni O, Chen Y, Veldman R, Jiang Y, Gooden GC, Ethier SP, Kallioniemi A and Kallioniemi OP: Comparative genomic hybridization analysis of 38 breast cancer cell lines: A basis for interpreting complementary DNA microarray data. Cancer Res. 60:4519–4525. 2000.PubMed/NCBI

19 

Gown AM, Goldstein LC, Barry TS, Kussick SJ, Kandalaft PL, Kim PM and Tse CC: High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol. 21:1271–1277. 2008. View Article : Google Scholar : PubMed/NCBI

20 

Waye JS and Willard HF: Structure, organization, and sequence of alpha satellite DNA from human chromosome 17: Evidence for evolution by unequal crossing-over and an ancestral pentamer repeat shared with the human X chromosome. Mol Cell Biol. 6:3156–3165. 1986. View Article : Google Scholar : PubMed/NCBI

21 

Choo KH, Brown R, Webb G, Craig IW and Filby RG: Genomic organization of human centromeric alpha satellite DNA: Characterization of a chromosome 17 alpha satellite sequence. DNA. 6:297–305. 1987. View Article : Google Scholar : PubMed/NCBI

22 

Gonzalez Garcia JR and Meza-Espinoza JP: Use of the international system for human cytogenetic nomenclature (ISCN). Blood. 108:3952–3953; author reply 3953. 2006. View Article : Google Scholar : PubMed/NCBI

23 

Gao M, Pang H, Zhao YH, Hua J, Tong D, Zhao H, Liu Y, Zhao Y, Zhang M, Yan XJ, et al: Karyotype analysis in large sample cases from Shenyang Women's and Children's hospital: A study of 16,294 male infertility patients. Andrologia. 49:2017. View Article : Google Scholar

24 

Espinosa R III and Le Beau MM: Gene mapping by FISH. Methods Mol Biol. 68:53–76. 1997.PubMed/NCBI

25 

Visscher DW, Wallis T and Ritchie CA: Detection of chromosome aneuploidy in breast lesions with fluorescence in situ hybridization: comparison of whole nuclei to thin tissue sections and correlation with flow cytometric DNA analysis. Cytometry. 21:95–100. 1995. View Article : Google Scholar : PubMed/NCBI

26 

Cheng SS and Cheng YC: An ordered relation between the ANOVA estimator of the intraclass correlation and a kappa-type statistic in binary data. Stat Probab Lett. 38:275–280. 2010. View Article : Google Scholar

27 

Pathmanathan N and Bilous AM: HER2 testing in breast cancer: An overview of current techniques and recent developments. Pathology. 44:587–595. 2012. View Article : Google Scholar : PubMed/NCBI

28 

O'Grady A, Allen D, Happerfield L, Johnson N, Provenzano E, Pinder SE, Tee L, Gu M and Kay EW: An immunohistochemical and fluorescence in situ hybridization-based comparison between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and United Kingdom HER2 IHC scoring guidelines. Appl Immunohistochem Mol Morphol. 18:489–493. 2010. View Article : Google Scholar : PubMed/NCBI

29 

Yoon N, Do IG and Cho EY: Analysis of HER2 status in breast carcinoma by fully automated HER2 fluorescence in situ hybridization (FISH): Comparison of two immunohistochemical tests and manual FISH. APMIS. 122:755–760. 2014. View Article : Google Scholar : PubMed/NCBI

30 

Hyun CL, Lee HE, Kim KS, Kim SW, Kim JH, Choe G and Park SY: The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol. 61:317–321. 2008. View Article : Google Scholar : PubMed/NCBI

31 

Marchiò C, Lambros MB, Gugliotta P, Di Cantogno LV, Botta C, Pasini B, Tan DS, Mackay A, Fenwick K, Tamber N, et al: Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol. 219:16–24. 2009. View Article : Google Scholar : PubMed/NCBI

32 

Moelans CB, de Weger RA and van Diest PJ: Absence of chromosome 17 polysomy in breast cancer: Analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res Treat. 120:1–7. 2010. View Article : Google Scholar : PubMed/NCBI

33 

Yeh IT, Martin MA, Robetorye RS, Bolla AR, McCaskill C, Shah RK, Gorre ME, Mohammed MS and Gunn SR: Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol. 22:1169–1175. 2009. View Article : Google Scholar : PubMed/NCBI

34 

Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB III, Carrato A, Gulley ML, Jain D, Kakar S, et al: HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: Guideline from the college of American Pathologists, American Society for clinical pathology, and the American Society of clinical oncology. J Clin Oncol. 35:446–464. 2017. View Article : Google Scholar : PubMed/NCBI

35 

Tse CH, Hwang HC, Goldstein LC, Kandalaft PL, Wiley JC, Kussick SJ and Gown AM: Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: Implications for anti-HER2 targeted therapy. J Clin Oncol. 29:4168–4174. 2011. View Article : Google Scholar : PubMed/NCBI

36 

Jang MH, Kim EJ, Kim HJ, Chung YR and Park SY: Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number. Breast Cancer Res Treat. 153:67–77. 2015. View Article : Google Scholar : PubMed/NCBI

37 

Sneige N, Hess KR, Multani AS, Gong Y and Ibrahim NK: Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study. Cancer. 123:1115–1123. 2017. View Article : Google Scholar : PubMed/NCBI

38 

Donaldson AR, Shetty S, Wang Z, Rivera CL, Portier BP, Budd GT, Downs-Kelly E, Lanigan CP and Calhoun BC: Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer. Cancer. 123:2230–2239. 2017. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2019
Volume 18 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Xu, Z., Xu, P., Fan, W., Huang, B., Cheng, Q., Zhang, Z. ... Yu, M. (2019). The effect of an alternative chromosome 17 probe on fluorescence in situ hybridization for the assessment of HER2 amplification in invasive breast cancer. Experimental and Therapeutic Medicine, 18, 2095-2103. https://doi.org/10.3892/etm.2019.7756
MLA
Xu, Z., Xu, P., Fan, W., Huang, B., Cheng, Q., Zhang, Z., Wang, P., Yu, M."The effect of an alternative chromosome 17 probe on fluorescence in situ hybridization for the assessment of HER2 amplification in invasive breast cancer". Experimental and Therapeutic Medicine 18.3 (2019): 2095-2103.
Chicago
Xu, Z., Xu, P., Fan, W., Huang, B., Cheng, Q., Zhang, Z., Wang, P., Yu, M."The effect of an alternative chromosome 17 probe on fluorescence in situ hybridization for the assessment of HER2 amplification in invasive breast cancer". Experimental and Therapeutic Medicine 18, no. 3 (2019): 2095-2103. https://doi.org/10.3892/etm.2019.7756